241 related articles for article (PubMed ID: 25916869)
1. Posterior subcapsular prostate cancer: identification with mpMRI and MRI/TRUS fusion-guided biopsy.
Sankineni S; George AK; Brown AM; Rais-Bahrami S; Wood BJ; Merino MJ; Pinto PA; Choyke PL; Turkbey B
Abdom Imaging; 2015 Oct; 40(7):2557-65. PubMed ID: 25916869
[TBL] [Abstract][Full Text] [Related]
2. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric magnetic resonance imaging (MRI) and subsequent MRI/ultrasonography fusion-guided biopsy increase the detection of anteriorly located prostate cancers.
Volkin D; Turkbey B; Hoang AN; Rais-Bahrami S; Yerram N; Walton-Diaz A; Nix JW; Wood BJ; Choyke PL; Pinto PA
BJU Int; 2014 Dec; 114(6b):E43-E49. PubMed ID: 24712649
[TBL] [Abstract][Full Text] [Related]
4. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis.
Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM
Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878
[TBL] [Abstract][Full Text] [Related]
6. Can MRI/TRUS fusion targeted biopsy replace saturation prostate biopsy in the re-evaluation of men in active surveillance?
Pepe P; Garufi A; Priolo G; Pennisi M
World J Urol; 2016 Sep; 34(9):1249-53. PubMed ID: 26699628
[TBL] [Abstract][Full Text] [Related]
7. Central zone lesions on magnetic resonance imaging: Should we be concerned?
Tan WP; Mazzone A; Shors S; Antoine N; Ekbal S; Khare N; McKiel C; Pessis D; Deane L
Urol Oncol; 2017 Jan; 35(1):31.e7-31.e12. PubMed ID: 27692837
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen.
Radtke JP; Schwab C; Wolf MB; Freitag MT; Alt CD; Kesch C; Popeneciu IV; Huettenbrink C; Gasch C; Klein T; Bonekamp D; Duensing S; Roth W; Schueler S; Stock C; Schlemmer HP; Roethke M; Hohenfellner M; Hadaschik BA
Eur Urol; 2016 Nov; 70(5):846-853. PubMed ID: 26810346
[TBL] [Abstract][Full Text] [Related]
9. 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies.
Piert M; Montgomery J; Kunju LP; Siddiqui J; Rogers V; Rajendiran T; Johnson TD; Shao X; Davenport MS
J Nucl Med; 2016 Jul; 57(7):1065-70. PubMed ID: 26985061
[TBL] [Abstract][Full Text] [Related]
10. Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification.
Muthigi A; Sidana A; George AK; Kongnyuy M; Shakir N; Kadakia M; Maruf M; Frye TP; Mertan F; Su D; Merino MJ; Choyke PL; Turkbey B; Wood BJ; Pinto PA
Int Urol Nephrol; 2016 Sep; 48(9):1445-52. PubMed ID: 27305918
[TBL] [Abstract][Full Text] [Related]
11. Cognitive MRI-TRUS fusion-targeted prostate biopsy according to PI-RADS classification in patients with prior negative systematic biopsy results.
Lai WJ; Wang HK; Liu HT; Park BK; Shen SH; Lin TP; Chung HJ; Huang YH; Chang YH
J Chin Med Assoc; 2016 Nov; 79(11):618-624. PubMed ID: 27567440
[TBL] [Abstract][Full Text] [Related]
12. Imaging and pathology findings after an initial negative MRI-US fusion-guided and 12-core extended sextant prostate biopsy session.
Hong CW; Walton-Diaz A; Rais-Bahrami S; Hoang AN; Türkbey B; Stamatakis L; Xu S; Amalou H; Siddiqui MM; Nix JW; Vourganti S; Merino MJ; Choyke PL; Wood BJ; Pinto PA
Diagn Interv Radiol; 2014; 20(3):234-8. PubMed ID: 24509182
[TBL] [Abstract][Full Text] [Related]
13. Combined T2 and diffusion-weighted MR imaging with template prostate biopsies in men suspected with prostate cancer but negative transrectal ultrasound-guided biopsies.
Sheikh N; Wei C; Szewczyk-Bieda M; Campbell A; Memon S; Lang S; Nabi G
World J Urol; 2017 Feb; 35(2):213-220. PubMed ID: 27236302
[TBL] [Abstract][Full Text] [Related]
14. Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect Lesions.
Kachanov M; Leyh-Bannurah SR; Roberts MJ; Sauer M; Beyersdorff D; Boiko S; Maurer T; Steuber T; Graefen M; Budäus L
J Urol; 2022 Feb; 207(2):333-340. PubMed ID: 34555925
[TBL] [Abstract][Full Text] [Related]
15. In patients with a previous negative prostate biopsy and a suspicious lesion on magnetic resonance imaging, is a 12-core biopsy still necessary in addition to a targeted biopsy?
Salami SS; Ben-Levi E; Yaskiv O; Ryniker L; Turkbey B; Kavoussi LR; Villani R; Rastinehad AR
BJU Int; 2015 Apr; 115(4):562-70. PubMed ID: 25252133
[TBL] [Abstract][Full Text] [Related]
16. Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate.
Costa DN; Goldberg K; Leon AD; Lotan Y; Xi Y; Aziz M; Freifeld Y; Margulis V; Raj G; Roehrborn CG; Hornberger B; Desai N; Bagrodia A; Francis F; Pedrosa I; Cadeddu JA
Eur Urol Oncol; 2019 Jul; 2(4):397-404. PubMed ID: 31277776
[TBL] [Abstract][Full Text] [Related]
17. [Real-time MRI/US fusion-guided biopsy in biopsy-naïve and pre-biopsied patients with suspicion for prostate cancer].
Maxeiner A; Stephan C; Fischer T; Durmus T; Kilic E; Asbach P; Haas M; Günzel K; Neymeyer J; Miller K; Cash H
Aktuelle Urol; 2015 Jan; 46(1):34-8. PubMed ID: 25519051
[TBL] [Abstract][Full Text] [Related]
18. Reduced Core Targeted (RCT) biopsy: Combining multiparametric magnetic resonance imaging - transrectal ultrasound fusion targeted biopsy with laterally-directed sextant biopsies - An alternative template for prostate fusion biopsy.
Aminsharifi A; Gupta RT; Tsivian E; Sekar S; Sze C; Polascik TJ
Eur J Radiol; 2019 Jan; 110():7-13. PubMed ID: 30599876
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Value of Guided Biopsies: Fusion and Cognitive-registration Magnetic Resonance Imaging Versus Conventional Ultrasound Biopsy of the Prostate.
Oberlin DT; Casalino DD; Miller FH; Matulewicz RS; Perry KT; Nadler RB; Kundu S; Catalona WJ; Meeks JJ
Urology; 2016 Jun; 92():75-9. PubMed ID: 26966043
[TBL] [Abstract][Full Text] [Related]
20. An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience.
Costa DN; Kay FU; Pedrosa I; Kolski L; Lotan Y; Roehrborn CG; Hornberger B; Xi Y; Francis F; Rofsky NM
Urol Oncol; 2017 Apr; 35(4):149.e15-149.e21. PubMed ID: 27939349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
